Page 730 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

708 PART IV Specific Malignancies in the Small Animal Patient

VetBooks.ir TABLE 33.5 Summary of Response for Rescue Protocols —cont’d
a
Median
Number of Overall Response Complete Response Median Duration of
PRIVATE Protocol Animals (%) Response (%) Duration c Complete Response References
DMAC (dexametha- 54 72 44 61 days 112 days 309
sone, melphalan, 86 43 16 24 days NR 306
actinomycin-D,
cytosine arabi-
noside)
Lomustine (CCNU) 43 27 7 86 days 110 days 314
Lomustine, 48 77 65 70 days 90 days 319
l-asparaginase,
prednisone
Lomustine, 31 87 52 63 days 111 days 320
l-asparaginase,
prednisone
Lomustine, DTIC 57 35 23 62 days 83 days 312
Mitoxantrone 44 41 30 NR 127 days 315
MOPP (mech- 117 65 31 61 days 63 days 318
lorethamine,
vincristine,
procarbazine,
prednisone)
MPP (mechlor- 41 34 17 56 days 238 days 317
ethamine,
procarbazine,
prednisone)
MOMP (mech- 88 51 12 56 days 81 days 301
lorethamine,
vincristine,
melphalan,
prednisone)
LOPP (lomustine, 33 61 36 84 days NR 302
vincristine,
procarbazine,
prednisone)
Vinblastine (second 39 25.6 7.7 30 days NR 304
rescue)
Rabacfosadine (B 50 74 45 108 days 203 days 270
cell only)
LPP (lomustine, 41 61 29 34 days 84 days 307
procarbazine,
prednisone)

Temozolomide 26 32 13 15 days NR 308
a Minimum of 25 cases. Few of these protocols include sufficient numbers for adequate statistical power and fewer compare treatment protocols in a randomized prospective fashion. In addition, staging,
inclusion, and response criteria vary considerably between protocols presented. Therefore evaluations of efficacy between the various protocols are subject to bias making direct comparisons difficult and
indeed precarious.
b Prednisone often used concurrently.
c Various temporal response end-points were used including disease-free interval, time to progression, progression-free survival, time to discontinuation, and remission duration.